Literature DB >> 19084540

Structure-function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant.

Yohei Mukai1, Hiroko Shibata, Teruya Nakamura, Yasuo Yoshioka, Yasuhiro Abe, Tetsuya Nomura, Madoka Taniai, Tsunetaka Ohta, Shinji Ikemizu, Shinsaku Nakagawa, Shin-ichi Tsunoda, Haruhiko Kamada, Yuriko Yamagata, Yasuo Tsutsumi.   

Abstract

Tumor necrosis factor (TNF) is an important cytokine that suppresses carcinogenesis and excludes infectious pathogens to maintain homeostasis. TNF activates its two receptors [TNF receptor (TNFR) 1 and TNFR2], but the contribution of each receptor to various host defense functions and immunologic surveillance is not yet clear. Here, we used phage display techniques to generate receptor-selective TNF mutants that activate only one TNFR. These TNF mutants will be useful in the functional analysis of TNFR. Six amino acids in the receptor binding interface (near TNF residues 30, 80, and 140) were randomly mutated by polymerase chain reaction. Two phage libraries comprising over 5 million TNF mutants were constructed. By selecting the mutants without affinity for TNFR1 or TNFR2, we successfully isolated 4 TNFR2-selective candidates and 16 TNFR1-selective candidates, respectively. The TNFR1-selective candidates were highly mutated near residue 30, whereas TNFR2-selective candidates were highly mutated near residue 140, although both had conserved sequences near residues 140 and 30, respectively. This finding suggested that the phage display technique was suitable for identifying important regions for the TNF interaction with TNFR1 and TNFR2. Purified clone R1-6, a TNFR1-selective candidate, remained fully bioactive and had full affinity for TNFR1 without activating TNFR2, indicating the usefulness of the R1-6 TNF mutant in analyzing TNFR1 receptor function. To further elucidate the receptor selectivity of R1-6, we examined the structure of R1-6 by X-ray crystallography. The results suggested that R31A and R32G mutations strongly influenced electrostatic interaction with TNFR2, and that L29K mutation contributed to the binding of R1-6 to TNFR1. This phage display technique can be used to efficiently construct functional mutants for analysis of the TNF structure-function relationship, which might facilitate in silico drug design based on receptor selectivity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19084540     DOI: 10.1016/j.jmb.2008.11.053

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  24 in total

Review 1.  TNF receptor 2 pathway: drug target for autoimmune diseases.

Authors:  Denise Faustman; Miriam Davis
Journal:  Nat Rev Drug Discov       Date:  2010-05-21       Impact factor: 84.694

2.  Rational design of TNFα binding proteins based on the de novo designed protein DS119.

Authors:  Cheng Zhu; Changsheng Zhang; Tao Zhang; Xiaoling Zhang; Qi Shen; Bo Tang; Huanhuan Liang; Luhua Lai
Journal:  Protein Sci       Date:  2016-09-13       Impact factor: 6.725

3.  Enriching the human apoptosis pathway by predicting the structures of protein-protein complexes.

Authors:  Saliha Ece Acuner Ozbabacan; Ozlem Keskin; Ruth Nussinov; Attila Gursoy
Journal:  J Struct Biol       Date:  2012-02-14       Impact factor: 2.867

4.  Elucidating glycosaminoglycan-protein-protein interactions using carbohydrate microarray and computational approaches.

Authors:  Claude J Rogers; Peter M Clark; Sarah E Tully; Ravinder Abrol; K Christopher Garcia; William A Goddard; Linda C Hsieh-Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-31       Impact factor: 11.205

5.  Correlating RANK ligand/RANK binding kinetics with osteoclast formation and function.

Authors:  Julia T Warren; Wei Zou; Corinne E Decker; Nidhi Rohatgi; Christopher A Nelson; Daved H Fremont; Steven L Teitelbaum
Journal:  J Cell Biochem       Date:  2015-11       Impact factor: 4.429

6.  Unraveling the binding mechanism of trivalent tumor necrosis factor ligands and their receptors.

Authors:  Carlos R Reis; Aart H G van Assen; Wim J Quax; Robbert H Cool
Journal:  Mol Cell Proteomics       Date:  2010-09-17       Impact factor: 5.911

Review 7.  Tumor Necrosis Factor-Alpha and Pregnancy: Focus on Biologics. An Updated and Comprehensive Review.

Authors:  Jaume Alijotas-Reig; Enrique Esteve-Valverde; Raquel Ferrer-Oliveras; Elisa Llurba; Josep Maria Gris
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

Review 8.  Insights into the biology and therapeutic implications of TNF and regulatory T cells.

Authors:  Benoit L Salomon
Journal:  Nat Rev Rheumatol       Date:  2021-07-05       Impact factor: 20.543

9.  Arctigenin protects against depression by inhibiting microglial activation and neuroinflammation via HMGB1/TLR4/NF-κB and TNF-α/TNFR1/NF-κB pathways.

Authors:  Xiang Xu; Hu-Nan Piao; Fumie Aosai; Xiao-Yu Zeng; Jia-Hui Cheng; Yue-Xian Cui; Jing Li; Juan Ma; Hu-Ri Piao; Xuejun Jin; Lian-Xun Piao
Journal:  Br J Pharmacol       Date:  2020-10-19       Impact factor: 8.739

10.  Structural basis for treating tumor necrosis factor α (TNFα)-associated diseases with the therapeutic antibody infliximab.

Authors:  Shuaiyi Liang; Jianxin Dai; Sheng Hou; Lishu Su; Dapeng Zhang; Huaizu Guo; Shi Hu; Hao Wang; Zihe Rao; Yajun Guo; Zhiyong Lou
Journal:  J Biol Chem       Date:  2013-03-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.